维立志博-B(09887)：LBL-024于铂耐药卵巢癌IB/II期试验的首例患者用药
LEADS BIOLABS-BLEADS BIOLABS-B(HK:09887) 智通财经网·2025-12-23 08:37

Core Viewpoint - The announcement from Valiant Biopharma-B (09887) indicates the successful administration of Opalizumab (PD-L1/4-1BB bispecific antibody LBL-024) to the first patient in a Phase Ib/II clinical trial for platinum-resistant ovarian cancer [1] Group 1 - The clinical trial is an open-label, multicenter Phase Ib/II study led by Professor Wu Lingying from the Cancer Hospital of the Chinese Academy of Medical Sciences [1] - The trial is being conducted simultaneously across multiple hospitals in China [1] - The objective of the trial is to evaluate the efficacy and safety of Opalizumab in combination with paclitaxel for patients with platinum-resistant ovarian cancer [1]